Targets › SLC6A4
85 programs from 69 companies in 187 trials: 74 Phase 2, 49 Phase 4, 33 Phase 1, 31 Phase 3; Psychiatry, Oncology, Neurology; next expected readout Nov 2026.
Serotonin transporter that cotransports serotonin with one Na(+) ion in exchange for one K(+) ion and possibly one proton in an overall electroneutral transport cycle. Transports serotonin across the plasma membrane from the extracellular compartment to the cytosol thus limiting serotonin intercellular signaling. (UniProt, P31645)
Open in Phaseline: the race on SLC6A4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Pennsylvania | Venlafaxine Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 4 | Posttraumatic Stress Disorder | Nov 2026 |
| University of Pennsylvania | paroxetine Serotonin transporter inhibitor | SLC6A4 | Phase 4 | Posttraumatic Stress Disorder | Nov 2026 |
| Brigham and Women's Hospital | MIB 626 (NMN) Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist | SLC5A2, SLC6A2, GLP1R, UNKNOWN, Tubulin, OPRM1, NR3C2, AGTR1, IL4R, SLC6A4, HTR2A, HTR2C | Phase 4 | Prostate Cancer; Stable Coronary Disease; Allergic Contact Dermatitis; Hypertension … | Nov 2026 |
| All India Institute of Medical Sciences, Bhubaneswar | Dosulepin Tricyclic antidepressant with serotonin and norepinephrine reuptake inhibition | SLC6A4, SLC6A2 | Phase 4 | Somatic Symptom Disorder (DSM-V) | Nov 2026 |
| All India Institute of Medical Sciences, Bhubaneswar | Venlafaxine Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 4 | Somatic Symptom Disorder (DSM-V) | Nov 2026 |
| University of Pennsylvania | 2-[18F]-FA Voltage-gated calcium channel modulator | CHRNA4, OPRK1, OPRD1, OPRM1, UL51, ADRA2A, ADRA2C, ADRA2B, Ion channels, CACNB4, CACNB2, CACNB1, CACNB3, TNF, SLC6A4, HTR2A, HTR2C, FKBP1A, CD86, CD80, PDE4A, PDE4D, PDE4B, PDE4C, PDE3A, CHRNB2, STN | Phase 4 | Alcohol Use Disorder; Acute Kidney Injury; Insomnia; Giant Cell Arteritis … | Nov 2026 |
| University of Miami | Duloxetine Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 4 | THA | Dec 2026 |
| University of Cincinnati | Escitalopram Serotonin transporter inhibitor | SLC6A4 | Phase 4 | Anxiety | Dec 2026 |
| Medical University of Vienna | Escitalopram Serotonin transporter inhibitor | SLC6A4 | Phase 4 | Major Depressive Disorder (MDD) | Dec 2026 |
| Emine Kanmaz | Sertraline Serotonin transporter inhibitor | SLC6A4 | Phase 4 | Social Anxiety Disorder | Dec 2026 |
| NYU Langone Health | Escitalopram Oxalate Serotonin transporter inhibitor | SLC6A4 | Phase 4 | Alzheimer Disease | Dec 2026 |
| John D. Dingell VA Medical Center | Trazodone Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist | SLC6A4, HTR2A, HTR2C | Phase 4 | Sleep Apnea | Dec 2026 |
| Tongji University | trazodone Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist | SLC6A4, HTR2A, HTR2C | Phase 4 | Depressed Insomniac Co-morbid Patients | Dec 2026 |
| University of Florida | Fluoxetine Serotonin transporter inhibitor | SLC6A4 | Phase 4 | Musculoskeletal Injury | Mar 2027 |
| David Steffens | Desvenlafaxine Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 4 | Major Depressive Disorder | Apr 2027 |
| David Steffens | Sertraline Serotonin transporter inhibitor | SLC6A4 | Phase 4 | Major Depressive Disorder | Apr 2027 |
| Wake Forest University Health Sciences | Duloxetine Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 4 | Depression; Depression in Old Age | May 2027 |
| Montefiore Medical Center | Duloxetine Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 4 | Back Pain, Low | May 2027 |
| Wake Forest University Health Sciences | Fluoxetine Serotonin transporter inhibitor | SLC6A4 | Phase 4 | Depression | May 2027 |
| Shanghai Mental Health Center | Sertraline Serotonin transporter inhibitor | SLC6A4 | Phase 4 | Depression; Obsessive-Compulsive Disorder | Jun 2027 |
| Sunnybrook Health Sciences Centre | Duloxetine Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 4 | Knee Osteoarthritis | Jul 2027 |
| University of Texas at Austin | Sertraline Serotonin transporter inhibitor | SLC6A4 | Phase 4 | Major Depressive Disorder | Jul 2027 |
| The Chaim Sheba Medical Center | fluoxetin Selective serotonin reuptake inhibitor | SLC6A4 | Phase 4 | Velocardiofacial Syndrome | Aug 2027 |
| Aarhus University Hospital | Duloxetine Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 4 | Functional Disorder | Nov 2027 |
| Poznan University of Medical Sciences | Escitalopram Serotonin transporter inhibitor | SLC6A4 | Phase 4 | Depression - Major Depressive Disorder | Nov 2027 |
| Poznan University of Medical Sciences | Fluoxetine Serotonin transporter inhibitor | SLC6A4 | Phase 4 | Depression - Major Depressive Disorder | Nov 2027 |
| Poznan University of Medical Sciences | Sertraline Serotonin transporter inhibitor | SLC6A4 | Phase 4 | Depression - Major Depressive Disorder | Nov 2027 |
| University of California, Irvine | nortriptyline Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 4 | Ménière | Dec 2027 |
| Copenhagen University Hospital, Rigshospitalet | Escitalopram Serotonin transporter inhibitor | SLC6A4 | Phase 4 | Obsessive-Compulsive Disorder/High Compulsive Individuals | Dec 2027 |
| Northwestern University | Duloxetine Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 4 | Knee Osteoarthritis | Mar 2028 |
| Benedict Alter | Duloxetine Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 4 | Knee Osteoarthritis (Knee OA) | Dec 2028 |
| VA Office of Research and Development | Trazodone Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist | SLC6A4, HTR2A, HTR2C | Phase 4 | Sleep Disordered Breathing | Jun 2030 |
| Chinese University of Hong Kong | Trazodone Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist | SLC6A4, HTR2A, HTR2C | Phase 4 | Mild Cognitive Impairment | – |
| Ann & Robert H Lurie Children's Hospital of Chicago | escitalopram Serotonin transporter inhibitor | SLC6A4 | Phase 3 | Anxiety, Separation | Dec 2026 |
| Ann & Robert H Lurie Children's Hospital of Chicago | fluoxetine Serotonin transporter inhibitor | SLC6A4 | Phase 3 | Anxiety, Separation | Dec 2026 |
| Ann & Robert H Lurie Children's Hospital of Chicago | sertraline Serotonin transporter inhibitor | SLC6A4 | Phase 3 | Anxiety, Separation | Dec 2026 |
| Parc de Salut Mar | Duloxetine Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 3 | Chronic Post-surgical Pain | Dec 2026 |
| Harvard Medical School (HMS and HSDM) | fluoxetine Serotonin transporter inhibitor | SLC6A4 | Phase 3 | Depression | Dec 2026 |
| SK Life Science | Carisbamate GABA transporter 1 (GAT-1) inhibitor | SLC6A4 | Phase 3 | Seizures | Feb 2027 |
| Washington University School of Medicine | Fluvoxamine Serotonin transporter inhibitor | SLC6A4 | Phase 3 | Delirium | Apr 2027 |
| Intra-Cellular Therapies | Lumateperone Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist; Serotonin transporter inhibitor | HTR2A, DRD2, SLC6A4 | Phase 3 | Major Depressive Disorder; Irritability Associated With Autism Spectrum Disorder; Bipolar Depression; Schizophrenia … | Apr 2027 |
| Tanta University | Duloxetine Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 3 | Biliary Disease | Jun 2027 |
| Otsuka | Centanafadine (EB-1020) Monoamine transporter inhibitor | SLC6A4, SLC6A3, SLC6A2 | Phase 3 | Attention-Deficit Hyperactivity Disorder(ADHD); Attention Deficit Hyperactivity Disorder (ADHD) | Aug 2027 |
| Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Fluvoxamine Serotonin transporter inhibitor | SLC6A4 | Phase 3 | Post-COVID | Dec 2027 |
| Dr. Inge Winter | Escitalopram Serotonin transporter inhibitor | SLC6A4 | Phase 3 | Bipolar Depression | Jun 2028 |
| Dr. Inge Winter | Sertraline Serotonin transporter inhibitor | SLC6A4 | Phase 3 | Bipolar Depression | Jun 2028 |
| Dr. Inge Winter | Venlafaxine Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 3 | Bipolar Depression | Jun 2028 |
| Reinier de Graaf Groep | Venlafaxine Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 3 | Breast Cancer | Jan 2029 |
| Takeda | Vortioxetine Serotonin 1a (5-HT1a) receptor agonist; Serotonin transporter inhibitor; Serotonin 3a (5-HT3a) receptor antagonist | HTR1A, SLC6A4, HTR3A | Phase 3 | Major Depressive Disorder; Glioblastoma; Depression | Sep 2029 |
| JHSPH Center for Clinical Trials | Escitalopram Serotonin transporter inhibitor | SLC6A4 | Phase 3 | Dementia | – |
| Children's Hospital Los Angeles | Fluoxetine Serotonin transporter inhibitor | SLC6A4 | Phase 3 | Anxiety Disorders | – |
| Wright State University | Imipramine Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 2 | Rosacea; Photosensitivity; Imipramine | Dec 2026 |
| Mayo Clinic | Amitriptyline Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 2 | Interstitial Lung Disease; Refractory Chronic Cough | Dec 2026 |
| Polyclinique de l'Europe | Amitriptyline Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 2 | Inflammatory Bowel Diseases | Dec 2026 |
| M.D. Anderson Cancer Center | Duloxetine Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 2 | Chemotherapy-Induced Peripheral Neuropathy | Dec 2026 |
| Alliance for Clinical Trials in Oncology | Duloxetine Hydrochloride Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 2 | Stage II Colorectal Cancer AJCC v8 | Dec 2026 |
| First Affiliated Hospital of Chongqing Medical University | Sertraline Serotonin transporter inhibitor | SLC6A4 | Phase 2 | Major Depressive Disorder (MDD); Depression | Dec 2026 |
| University of Pennsylvania | Duloxetine Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 2 | Inflammatory Bowel Diseases | Mar 2027 |
| University of Michigan | Escitalopram Serotonin transporter inhibitor | SLC6A4 | Phase 2 | Irritable Bowel Syndrome With Constipation | Mar 2027 |
| Remedy | Midomafetamine Sodium-dependent dopamine transporter releasing agent; Sodium-dependent serotonin transporter releasing agent; Sodium-dependent noradrenaline transporter releasing agent | SLC6A3, SLC6A4, SLC6A2 | Phase 2 | Post Traumatic Stress Disorder | Mar 2027 |
| University of Nebraska | Escitalopram Serotonin transporter inhibitor | SLC6A4 | Phase 2 | Glioma of Brain | Jun 2027 |
| University of Utah | 5-hydroxytryptophan (5-HTP) Serotonin precursor; increases central serotonergic neurotransmission | SLC6A4 | Phase 2 | Major Depressive Disorder | Jul 2027 |
| Yan Yang, MD, Ph.D | Duloxetine Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 2 | Chemotherapy-induced Peripheral Neuropathy | Jul 2027 |
| Centre hospitalier de l'Université de Montréal (CHUM) | Trazodone Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist | SLC6A4, HTR2A, HTR2C | Phase 2 | Insomnia Chronic | Jul 2027 |
| Definium Therapeutics US | Midomafetamine (DT402) Sodium-dependent dopamine transporter releasing agent; Sodium-dependent serotonin transporter releasing agent; Sodium-dependent noradrenaline transporter releasing agent | SLC6A3, SLC6A4, SLC6A2 | Phase 2 | Autism Spectrum Disorder | Aug 2027 |
| Holland Bloorview Kids Rehabilitation Hospital | Sertraline Serotonin transporter inhibitor | SLC6A4 | Phase 2 | Neurodevelopmental Disorders | Sep 2027 |
| First Affiliated Hospital of Wenzhou Medical University | Fluoxetine Serotonin transporter inhibitor | SLC6A4 | Phase 2 | Hepatobiliary Malignancy | Oct 2027 |
| Memorial Sloan Kettering Cancer Center | Flibanserin Serotonin 1A receptor agonist, serotonin 2A receptor antagonist, and serotonin reuptake in | HTR1A, HTR2A, SLC6A4 | Phase 2 | Breast Cancer | Oct 2027 |
| University of Rochester | Duloxetine Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 2 | Painful Peripheral Neuropathy | Jun 2028 |
| Nova Scotia Health Authority | fluoxetine Serotonin transporter inhibitor | SLC6A4 | Phase 2 | Depression | Jun 2028 |
| Wright State University | Amitriptyline Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 2 | Rosacea | Dec 2028 |
| University of Texas Southwestern Medical Center | Escitalopram Serotonin transporter inhibitor | SLC6A4 | Phase 2 | Asthma | Dec 2028 |
| National Institute of Mental Health (NIMH) | Fluoxetine Serotonin transporter inhibitor | SLC6A4 | Phase 2 | Anxiety Disorders | Jan 2029 |
| University of Michigan | Amitriptyline Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 2 | Quiescent Crohn's Disease (CD) | Dec 2029 |
| Centre Hospitalier St Anne | Trazodone Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist | SLC6A4, HTR2A, HTR2C | Phase 2 | Depression - Major Depressive Disorder | Dec 2029 |
| AlgoTherapeutix | ATX01 10% Amitriptyline hydrochloride topical formulation; tricyclic antidepressant with analgesic p | SLC6A4, SLC6A3 | Phase 2 | Chemotherapy-induced Peripheral Neuropathy | – |
| Md. Moktadirul Hoque Shuvo | Amitriptyline Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 2 | Functional Dyspepsia | – |
| First Affiliated Hospital of Chongqing Medical University | Duloxetine Serotonin transporter inhibitor; Norepinephrine transporter inhibitor | SLC6A4, SLC6A2 | Phase 1 | Depression | Dec 2026 |
| First Affiliated Hospital of Chongqing Medical University | Fluoxetine Serotonin transporter inhibitor | SLC6A4 | Phase 1 | Depression | Dec 2026 |
| Resilient Pharmaceuticals | Midomafetamine Sodium-dependent dopamine transporter releasing agent; Sodium-dependent serotonin transporter releasing agent; Sodium-dependent noradrenaline transporter releasing agent | SLC6A3, SLC6A4, SLC6A2 | Phase 1 | Healthy Volunteers; Post-Traumatic Stress Disorder; PTSD, Post Traumatic Stress Disorder; Obsessive-Compulsive Disorder … | Feb 2027 |
| Jonsson Comprehensive Cancer Center | Fluoxetine Serotonin transporter inhibitor | SLC6A4 | Phase 1 | Colorectal Adenocarcinoma | Jul 2027 |
| Yale University | Fluoxetine Serotonin transporter inhibitor | SLC6A4 | Phase 1 | Obsessive-Compulsive Disorder | Sep 2027 |
| Deepak C. D'Souza | DMT Serotonin receptor agonist; hallucinogenic indoleamine | SLC6A4 | Phase 1 | Major Depression Disorder | Dec 2027 |
| Icahn School of Medicine at Mount Sinai | MDMA-AT-BN MDMA-assisted psychotherapy specific to bulimia nervosa | SLC6A4 | Phase 1 | Bulimia Nervosa | Apr 2028 |
| Rachel Yehuda | MDMA Hydrochloride Serotonin-norepinephrine-dopamine releasing agent; promotes prosocial behavior and emotion | SLC6A4, SLC6A2, SLC6A3 | Phase 1 | Mental Wellbeing | Sep 2029 |
Depression (9) Major Depressive Disorder (6) Post Traumatic Stress Disorder (6) Depression - Major Depressive Disorder (5) Schizophrenia (5) Posttraumatic Stress Disorder (4) Bipolar Depression (4) Obstructive Sleep Apnea (4) Anxiety, Separation (3) Obsessive-Compulsive Disorder (3) Major Depressive Disorder (MDD) (2) Rosacea (2)
small molecule (82), mixed (2)
University of Pennsylvania (4) First Affiliated Hospital of Chongqing Medical University (3) Poznan University of Medical Sciences (3) Ann & Robert H Lurie Children's Hospital of Chicago (3) Dr. Inge Winter (3) Wright State University (2) University of Michigan (2) David Steffens (2) Wake Forest University Health Sciences (2) All India Institute of Medical Sciences, Bhubaneswar (2) Aarhus University Hospital (1) Parc de Salut Mar (1) Rachel Yehuda (1) University of Miami (1) Intra-Cellular Therapies (1) The Chaim Sheba Medical Center (1) SK Life Science (1) Memorial Sloan Kettering Cancer Center (1) Reinier de Graaf Groep (1) Northwestern University (1)
SLC6A2 (34) HTR2A (10) HTR2C (8) SLC6A3 (6) HTR1A (2) OPRM1 (2) DRD2 (1) SLC5A2 (1) GLP1R (1) UNKNOWN (1) Tubulin (1) NR3C2 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.